All In Biotech

Drug Trial Radar · NCT07047118

A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Lutetium (177Lu) Vipivotide Tetraxetan in Adult Male Patients With PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC)

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 138 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

138

Actual

Start

Jul 3, 2025

Primary completion

Jul 16, 2027

Study completion May 14, 2028

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jul 2, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase II study aims to evaluate the efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg QD doses + lutetium (177Lu) vipivotide tetraxetan (hereafter referred as AAA617) compared with AAA617 (control) in participants with metastatic Castration Resistant Prostate Cancer (mCRPC) with prior exposure to at least 1 Androgen Receptor Pathway Inhibitor (ARPI) and 0-2 taxane regimens and to select the recommended dose of the combination for phase III. Towards that end, the totality of the efficacy, safety, tolerability and pharmacokinetic (PK) data from participants randomized in the study will be evaluated.

Conditions

  • Prostatic Cancer, Castration-Resistant

Interventions

  • JSB462Drug

    Administered orally, daily and continuously (100 mg or 300 mg QD) until disease progression per PCWG3-modified RECIST v1.1 as assessed by the investigator, the occurrence of unacceptable toxicities, death, participant decision or investigator decision

  • AAA617Drug

    administered at 7.4 GBq intravenously every 6 weeks for up to 6 doses, unless there is disease progression per PCWG3-modified RECIST v1.1 as assessed by the investigator, the occurrence of unacceptable toxicities, death, participant decision or investigator decision

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Prostate Specific Antigen 50 (PSA50) RateTime frame: From date of randomization till 30 days safety fup, assessed up to approximately 30 months
  2. Incidence rate of adverse events (AEs)Time frame: From date of randomization till 30 days safety fup, assessed up to approximately 30 months
  3. Number of participants with dose adjustmentsTime frame: From date of randomization till 30 days safety fup, assessed up to approximately 30 months
  4. Duration of exposure to study treatmentTime frame: From date of randomization till 30 days safety fup, assessed up to approximately 30 months

Locations

44 sites in 15 countries. Site status is shown where the registry gives one.

  • City of Hope National Medical

    Duarte, California

  • Providence Saint Johns Health Ctr

    Santa Monica, California

  • Rocky Mountain Cancer Centers

    Denver, Colorado

  • Yale University School Of Medicine

    New Haven, Connecticut

  • Indiana University

    Indianapolis, Indiana

  • Massachusetts General Hospital

    Boston, Massachusetts

  • XCancer Omaha LLC

    Omaha, Nebraska

  • NYU Laura and Isaac Perlmutter Cancer Center

    New York, New York

  • Univ of Pittsburgh Cancer Institute

    Pittsburgh, Pennsylvania

  • Urology San Antonio

    San Antonio, Texas

  • Novartis Investigative Site

    Darlinghurst, New South Wales, Australia

  • Novartis Investigative Site

    Adelaide, South Australia, Australia

  • Novartis Investigative Site

    Melbourne, Victoria, Australia

  • Novartis Investigative Site

    Linz, Austria

  • Novartis Investigative Site

    Vienna, Austria

  • Novartis Investigative Site

    Innsbruck, Tyrol, Austria

  • Novartis Investigative Site

    Burnaby, British Columbia, Canada

  • Novartis Investigative Site

    Montreal, Quebec, Canada

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Prague, Czechia

  • Novartis Investigative Site

    Brest, France

  • Novartis Investigative Site

    Marseille, France

  • Novartis Investigative Site

    Tours, France

  • Novartis Investigative Site

    Essen, Germany

  • Novartis Investigative Site

    Rostock, Germany

  • Novartis Investigative Site

    Afula, Israel

  • Novartis Investigative Site

    Beersheba, Israel

  • Novartis Investigative Site

    Haifa, Israel

  • Novartis Investigative Site

    Jerusalem, Israel

  • Novartis Investigative Site

    Petah Tikva, Israel

  • Novartis Investigative Site

    Ramat Gan, Israel

  • Novartis Investigative Site

    Genova, GE, Italy

  • Novartis Investigative Site

    Roma, RM, Italy

  • Novartis Investigative Site

    Hoofddorp, Netherlands

  • Novartis Investigative Site

    Nijmegen, Gerlderland, Netherlands

  • Novartis Investigative Site

    Singapore, Singapore

  • Novartis Investigative Site

    Seoul, South Korea

  • Novartis Investigative Site

    Seoul, South Korea

  • Novartis Investigative Site

    Barcelona, Spain

Showing 40 of 44 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.